W. Nothaft

发表

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

William H. Yang, J. Bernstein, W. Lumry, 2018, JAMA.

A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid‐Dispersion Formulations of the TRPV1 Antagonist ABT‐102, Relative to the Oral Solution Formulation, in Healthy Human Volunteers

S. Dutta, C. Locke, A. Othman, 2012, Clinical pharmacology in drug development.

Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain

M. Rowbotham, Y. Pritchett, B. Stacey, 2012, PAIN®.

A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain

M. Rowbotham, M. Backonja, W. Nothaft, 2009, PAIN.

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema.

R. Body, J. Bernstein, P. Levy, 2017, The journal of allergy and clinical immunology. In practice.

Erratum to: Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers

S. Dutta, G. An, W. Awni, 2015, The AAPS Journal.

Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers

S. Dutta, G. An, W. Awni, 2015, The AAPS Journal.

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults.

M. Wallace, C. Locke, W. Nothaft, 2015, Pain medicine.

Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial

J. Serra, R. Solà, C. Locke, 2015, Pain.

A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain

D. Ziegler, G. An, W. Nothaft, 2015, Pain.

Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.

W. Aberer, J. Bernstein, H. Farkas, 2017, The journal of allergy and clinical immunology. In practice.

Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial

M. Rowbotham, P. Svensson, C. Faltynek, 2011, PAIN.

Erratum to: Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers

S. Dutta, G. An, W. Awni, 2015, The AAPS Journal.

Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers

S. Dutta, G. An, W. Awni, 2014, The AAPS Journal.

Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.

S. Dutta, A. Othman, W. Awni, 2013, British journal of clinical pharmacology.

Pharmacokinetics of the TRPV1 Antagonist ABT‐102 in Healthy Human Volunteers: Population Analysis of Data From 3 Phase 1 Trials

S. Dutta, W. Nothaft, Walid M. Awni, 2012, Journal of clinical pharmacology.

An oral TRPV1 antagonist attenuates laser radiant‐heat‐evoked potentials and pain ratings from UVB‐inflamed and normal skin

P. Reeh, C. Locke, A. Othman, 2013, British journal of clinical pharmacology.

Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in Adults: 8

R. Body, J. Bernstein, P. Levy, 2016 .